A donor who wishes to remain anonymous has provided a landmark $25 million gift to Children’s Hospital Los Angeles (CHLA) to support the cognitive, emotional and behavioral health needs of CHLA patients.
Setmore has released a new report on the vital role of online appointment scheduling, as it continues to aid business continuity during the global pandemic.
Drug Guardians' community now offers extensive information about a growing number of lawsuits against what's called "big pharma," giant pharmaceutical companies.Vista, CA, Jan. 26, 2021 (GLOBE NEWSWIRE) -- The pharmaceutical industry is worth billions of dollars in the US alone. However, "Big Pharma's" reach is beyond US borders. While the industry has been credited with developing innovative and beneficial drugs currently being used across the world, the companies are also embroiled in dozens of lawsuits in the US alone. The cases include residents of just about every state that alleged negligence, deception, and the fraudulent methods adopted by companies to push drug sales. The often alleged, illegal, and fraudulent practices risk general public health and are of grave concern to every American. Over the past couple of years, it is also alleged that Big Pharma has been involved in the manipulation of healthcare providers, thus costing the government exchequer billions of dollars. Often health care workers aren't aware of the many adverse effects associated with a drug. In the interest of public knowledge and wellbeing, Drug Guardians have compiled and maintain a running list of the most controversial class-action lawsuits involving Big Pharma. Looking through the list of lawsuits complied by Drug Guardians, it is hard not to see some big-name brands with global reach. There are dozens of lawsuits and cases to review ranging from all types of claims and warnings to users regarding drug interactions and potential side-effects. Readers can browse through a complete list of current and past lawsuits against Big Pharma by visiting Drug Guardians' official website https://drugguardians.com. Drug Guardians hopes that the list will help people who were victims of drugs that caused severe adverse effects, which were never mentioned come forward. The list will also serve as a warning for people who may have just started to use any one of the drugs now part of the latest lawsuits. "The best way for anyone to protect themselves is to make sure that they are armed with information, and Drug Guardians is working hard to do just that." Said a spokesperson for Drug Guardians. About Drug Guardians Drug Guardians was founded to help consumers stand up for their rights when they are victims of negligence or intentional deception on the part of drug and medical device manufacturers. Drug Guardians partners with a nationwide network of licensed and insured attorneys with extensive experience advocating and upholding the rights of consumers and their loved ones. Drug Guardians encourages victims of Big Pharma to come forth to file a lawsuit or join an existing one. ### Contact Drug Guardians Phone: 800-628-7710 Website: https://drugguardians.com/ This news has been published for the above source. Drug Guardians [ID=16463] Disclaimer: The information does not constitute advice or an offer to buy. Any purchase made from this story is made at your own risk. Consult an expert advisor/health professional before any such purchase. Any purchase made from this link is subject to the final terms and conditions of the website's selling. The content publisher and its distribution partners do not take any responsibility directly or indirectly. If you have any complaints or copyright issues related to this article, kindly contact the company this news is about.
The importance of the pitch deck can't be underestimated. It is often the first point of contact between a company and venture investors, but how investors consume a pitch deck (and what they really think) is also a bit of a black box. Anyone can submit their pitch deck and hear what our guests, tech leaders across the industry, think of them.
In 2015, high-flying dealmaker Andrea Orcel declared in an interview that he wanted to be the chief executive of a bank. The last time Europe was on the verge of an economic crisis, Orcel was at the heart of the action. Now set to be named chief executive of Italy's second-biggest lender UniCredit, all eyes will be on which deals he does - or doesn't - want to do.
NEW YORK, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017 and November 30, 2020, inclusive (the “Class Period”). To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=minerva-neurosciences-inc&id=2513 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action. 如果您想加入这个集体诉讼案，请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=minerva-neurosciences-inc&id=2513 According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: the truth about the feedback received from the FDA concerning the “end-of-Phase 2” meeting; the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; the Company’s plan to use the combination of the Phase 2b and Phase 3 studies would be “highly unlikely” to support the submission of an NDA; reliance on these two trials in the submission of an NDA would lead to “substantial review issues” because the trials were inadequate and not well-controlled; and as a result, the Company’s public statements were materially false and misleading at all relevant times. If you wish to serve as lead plaintiff, you must move the Court no later than February 8, 2021. Lead plaintiff status is not required to seek compensation. You may retain counsel of your choice. You may remain an absent class member and take no action at this time. Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes. Zhang Investor Law P.C.99 Wall Street, Suite 232New York, New York 10005info@zhanginvestorlaw.comtel: (800) 991-3756
NEW YORK, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Tricida, Inc. (NASDAQ: TCDA) between September 4, 2019 and October 28, 2020, inclusive (the “Class Period”). To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=tricida-inc&id=2556 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action. 如果您想加入这个集体诉讼案，请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=tricida-inc&id=2556 If you wish to serve as lead plaintiff, you must move the Court before the March 8, 2021 DEADLINE. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that- Tricida’s NDA for veverimer was materially deficient; accordingly, it was foreseeably likely that the FDA would not accept the NDA for veverimer; and as a result, the Company’s public statements were materially false and misleading at all relevant times. Lead plaintiff status is not required to seek compensation. You may retain counsel of your choice. You may remain an absent class member and take no action at this time. Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes. Zhang Investor Law P.C.99 Wall Street, Suite 232New York, New York 10005info@zhanginvestorlaw.comtel: (800) 991-3756
The wealth of billionaires has gone up a ton during the pandemic because a surging stock market. AOL co-founder Steve Case weighs in.
NEW YORK, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Penumbra, Inc. (NYSE: PEN) between August 3, 2020 and December 15, 2020, inclusive (the “Class Period”). To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=penumbra-inc&id=2550 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action. 如果您想加入这个集体诉讼案，请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=penumbra-inc&id=2550 If you wish to serve as lead plaintiff, you must move the Court before the March 16, 2021 DEADLINE. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that- the Jet 7 Xtra Flex had known design defects that made it unsafe for its normal use; Penumbra did not adequately address the risk of Jet 7 Xtra Flex causing serious injury and deaths, which had in fact already occurred; the Jet 7 Xtra Flex was likely to be recalled due to its safety issues; and as a result, Penumbra’s public statements as set forth in the complaint were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. Lead plaintiff status is not required to seek compensation. You may retain counsel of your choice. You may remain an absent class member and take no action at this time. Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes. Zhang Investor Law P.C.99 Wall Street, Suite 232New York, New York 10005info@zhanginvestorlaw.comtel: (800) 991-3756
Bad news for Bed Bath & Beyond (NASDAQ: BBBY) shareholders: This morning, two separate Wall Street banks downgraded the stock, with Raymond James cutting its rating from strong buy to merely market perform (i.e., neutral), and Swiss banker UBS cutting the stock from neutral to sell. Bed Bath stock is up a stellar 13.8% as of 2 p.m. EST. Hearing an investment bank like Raymond James declaring Bed Bath & Beyond's valuation "stretched" (reports TheFly.com), or hearing UBS warn of the company's "deep" challenges that "will take time to fix" in the midst of a recession that has people spending less on home goods and furnishings, ordinarily sends investors running for the hills.
Good morning, and welcome to the Fourth Quarter Conference Call for Graco Inc. If you wish to access the replay for this call, you may do so by dialing 855-859-2056 within the United States or Canada. Graco has additional information available in the PowerPoint slide presentation, which is available as part of the webcast player.
Follow all the action live from St James’ Park
Tips from board-certified dermatologistsROSEMONT, Ill., Jan. 26, 2021 (GLOBE NEWSWIRE) -- For many people, winter skin probably conjures up images of dry, cracked hands, flaky skin, and windburn. However, the lips can be affected too. And while it may seem that dry, cracked lips are something you have to live with until spring, dermatologists from the American Academy of Dermatology say it’s possible to have soft, supple lips year-round by following a few simple steps. “Cold, dry weather; sun damage; and frequently licking your lips are just some of the reasons your lips might feel dry and chapped this winter,” says board-certified dermatologist Noëlle Sherber, MD, FAAD. “Understanding these causes and anything else that might trigger your chapped lips goes a long way in preventing and treating them.” To prevent and treat dry, chapped lips at home, Dr. Sherber recommends the following tips: Choose non-irritating lip products. Look for lip balms, lipsticks and other lip products that contain ingredients like castor seed oil, ceramides, dimethicone or mineral oil. Make sure your lip product is also labeled “fragrance free” and “hypoallergenic.” Avoid ingredients such as camphor, menthol or eucalyptus, as these can irritate your lips. If your lips burn, sting or tingle after using a lip product, stop using that product.Apply lip balm throughout the day and before you go to bed. If your lips are very dry and cracked, try a thick ointment, such as petroleum jelly. Ointment seals in moisture longer than waxes or oils.Protect your lips outdoors. Apply a lip balm with an SPF of 30 or higher before going outdoors, even in the winter. Look for a lip balm with titanium dioxide and/or zinc oxide and reapply it every two hours while outdoors.Keep your skin hydrated. Drink plenty of water and use a humidifier at home — especially in your bedroom while you sleep.Stop licking, biting or picking at your lips. When your lips feel dry, it may feel natural to wet them by licking them, but this can worsen the problem. When you catch yourself licking your lips, apply a non-irritating lip balm instead.Avoid holding metal items with your lips. Everyday items like paperclips, jewelry and reusable metal straws can irritate your lips. “Chapped lips are usually harmless, however sometimes they can be a sign of a medical condition,” says Dr. Sherber. “If your dry, chapped lips do not heal after following these tips for two to three weeks, talk to a board-certified dermatologist.” These tips are demonstrated in “How to Prevent and Treat Dry, Chapped Lips,” a video posted to the AAD website and YouTube channel. This video is part of the AAD’s “Video of the Month” series, which offers tips people can use to properly care for their skin, hair and nails. To find a board-certified dermatologist in your area, visit aad.org/findaderm. ContactNicole Dobkin, (847) 240-1746, ndobkin@aad.orgJulie Landmesser, (847) 240-1714, JLandmesser@aad.org More Information7 Dermatologists’ Tips for Healing Dry, Chapped LipsDry Skin Relief Dry Skin Relief from COVID-19 Handwashing About the AADHeadquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential, and most representative of all dermatologic associations. With a membership of more than 20,000 physicians worldwide, the AAD is committed to: advancing the diagnosis and medical, surgical and cosmetic treatment of the skin, hair and nails; advocating high standards in clinical practice, education, and research in dermatology; and supporting and enhancing patient care for a lifetime of healthier skin, hair and nails. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow the AAD on Facebook (American Academy of Dermatology), Twitter (@AADskin), Instagram (@AADskin1), or YouTube (AcademyofDermatology). Editor’s note: The AAD does not promote or endorse any products or services. This content is intended as editorial content and should not be embedded with any paid, sponsored or advertorial content as it could be perceived as an AAD endorsement. To view this release in a media-rich format, go to: https://aad.new-media-release.com/2021/chapped_lips/
St. Petersburg, FL, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Smith & Associates Real Estate agent, Melinda Pletcher, has been selected to The Tourist Development Council (TDC). The TDC is an advisory board to the Board of County Commissioners (BCC) that is tasked with making recommendations to the BCC on the use and expenditures of tourist development tax revenues; on the County's Tourist Development Plan, and on making recommendations about specific County tourism funding, among other things related to this vital, revenue-generating industry. Pletcher is a highly regarded member of the community serving as both a realtor and as a Commissioner for the municipality of St. Pete Beach. Having served the City of St. Pete Beach as Commissioner for three terms and holding her second term in office as the Vice Mayor, Pletcher astutely understands St. Pete and the beaches. She was chosen for the TDC due to her extensive knowledge of the area and will be working with other business leaders to strengthen the local economy and increase employment through the ongoing promotion and development of tourism. “Pinellas County’s number one industry is tourism. Not only does the tourism tax strengthen the local economy, but it also accounts for one out of every ten jobs. I am honored to serve on the TDC and help people in our area during this difficult time," said Melinda Pletcher, Realtor at Smith & Associates. The BCC as a whole appoints individual TDC members pursuant to state law and includes Mayor Rick Kriseman (St. Petersburg), Mayor Frank Hibbard (Clearwater), Mayor Julie Ward Bujalski (Dunedin), Commissioner Pat Gerard (Pinellas), and other prominent business leaders from the community and the local tourism agency, Visit St. Pete/Clearwater. CONTACT: Sarah Lesch Smith & Associates Real Estate 8137274077 sarah@playbookpublicrelations.com
•84.8% and 73.3% of women reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain at one year•Data to be included in New Drug Application submission to U.S. Food and Drug Administration anticipated in first half of 2021NEW YORK, LONDON,, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd., a majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that Myovant Sciences’ Phase 3 SPIRIT long-term extension study of the investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain over one year (52 weeks) with minimal and stable bone mineral density loss. The data are consistent with the efficacy and safety profile observed through 24 weeks in the Phase 3 SPIRIT 1 and SPIRIT 2 studies. These results will be included in the New Drug Application to the U.S. Food and Drug Administration for relugolix combination tablet for the treatment of women with endometriosis, anticipated to be submitted in the first half of 2021. Myovant is a healthcare company focused on redefining care for women and for men, and one of five healthcare companies in the Sumitovant family of companies. “This relugolix development milestone continues to further the mission of Sumitovant Biopharma to support the advancement of therapies that make a difference in the lives of patients, especially women of child-bearing years experiencing the pain of endometriosis, said Myrtle Potter, Chief Executive Officer of Sumitovant Biopharma. In the SPIRIT long-term extension study, 84.8% and 73.3% of women receiving relugolix combination therapy over one year achieved clinically meaningful pain reductions in dysmenorrhea and non-menstrual pelvic pain, respectively. On average, women reported an 82.8% reduction on the 11-point Numerical Rating Scale (0-10) for dysmenorrhea from 7.4 (severe pain) to 1.3 (mild pain) over one year. “Building on the strength of our one-year data of relugolix combination therapy in uterine fibroids, we are pleased by the one-year safety and efficacy data in women with endometriosis, which further our vision for a one pill, once-a-day treatment option suitable for long-term use in both diseases,” said Juan Camilo Arjona Ferreira, M.D., Chief Medical Officer of Myovant Sciences, Inc. “We look forward to submitting a New Drug Application for this potential new treatment for women with endometriosis in the first half of this year.” Bone mineral density remained stable through Week 52 in women treated with relugolix combination therapy after minimal, non-clinically meaningful bone loss through Week 24. The incidence of adverse events over one year was consistent with that observed in SPIRIT 1 and SPIRIT 2, with no new safety signals observed. The most commonly reported adverse events in at least 10% of women treated with relugolix combination therapy were headache, nasopharyngitis, and hot flashes. There was one pregnancy reported in the relugolix combination therapy group (n = 278). Data from SPIRIT 1 and SPIRIT 2 studies were previously presented at the American Society for Reproductive Medicine (ASRM) 2020 Virtual Congress. Complete results from the SPIRIT long-term extension study will be submitted for presentation at a future scientific meeting and publication in a medical journal. In December 2020, Myovant and Pfizer entered into a collaboration for the development and commercialization of relugolix in oncology and women’s health in the U.S. and Canada. Under the terms of the agreement, Myovant and Pfizer will jointly develop and commercialize ORGOVYXTM (relugolix) in advanced prostate cancer and, if approved, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in uterine fibroids and endometriosis. About the Phase 3 SPIRIT Program in Endometriosis The Phase 3 clinical program for endometriosis consists of two multinational, replicate pivotal clinical studies (SPIRIT 1 and SPIRIT 2) of relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in over 1,200 women with pain associated with endometriosis. Women received treatment either with relugolix combination therapy for 24 weeks, relugolix 40 mg once daily monotherapy for 12 weeks followed by relugolix combination therapy once daily for an additional 12 weeks, or placebo once daily for 24 weeks. Eligible women who completed the SPIRIT 1 or SPIRIT 2 studies were offered the opportunity to enroll in an active treatment extension study in which all women receive relugolix combination therapy for an additional 80-week period, resulting in a total treatment period of up to 104 weeks, designed to evaluate the safety and sustained efficacy of longer-term treatment. About Endometriosis Endometriosis is an estrogen-dependent, inflammatory disease in which tissue similar to the uterine lining is found outside the uterine cavity, commonly in the lower abdomen or pelvis, on ovaries, the bladder, and the colon. This endometrial-like tissue outside the uterus results in chronic inflammation and can cause scarring and adhesions. The symptoms associated with endometriosis include painful periods and chronic pelvic pain, painful ovulation, pain during or after sexual intercourse, heavy bleeding, fatigue, and infertility. Endometriosis can also impact general physical, mental, and social well-being, requiring a multi-disciplinary approach to care. For endometriosis-associated pain, per current guidelines, initial treatment options include hormonal contraceptives and over-the-counter pain medications. In more severe cases, LHRH agonists such as leuprolide acetate are used for short-term treatment. An estimated six million women in the U.S. suffer from symptoms of endometriosis, and an estimated one million women are inadequately treated by current medical therapy and require further treatment. Almost 200 million women are affected globally. About Myovant Sciences Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our lead product candidate, relugolix, is a once-daily, oral GnRH receptor antagonist. Relugolix (120 mg) is FDA-approved as ORGOVYX™ for adult patients with advanced prostate cancer. Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn. About Sumitovant Biopharma Ltd. Sumitovant Biopharma Ltd. is a global biopharmaceutical company with offices in New York City and London. Sumitovant is the majority shareholder of Myovant and Urovant, and wholly owns Enzyvant, Spirovant, and Altavant. Sumitovant's promising pipeline is comprised of early-through late-stage investigational medicines across a range of disease areas targeting high unmet need. Sumitovant is a wholly owned subsidiary of Sumitomo Dainippon Pharma. For further information about Sumitovant, please visit https://www.sumitovant.com. Follow Sumitovant on LinkedIn. About Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma is among the top-ten listed pharmaceutical companies in Japan, operating globally in major pharmaceutical markets, including Japan, the U.S., China, and the European Union. Sumitomo Dainippon Pharma is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more than 6,000 employees worldwide. Additional information about Sumitomo Dainippon Pharma is available through its corporate website at https://www.ds-pharma.com. Myovant Sciences Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In this press release, forward-looking statements include, but are not limited to, all statements and quotes reflecting Myovant Sciences’ expectations, including Myovant Sciences’ aspiration to redefine care for women and for men; the expected timing and strength of Myovant’s regulatory filings; the potential for relugolix combination therapy to significantly and durably reduce pain in women with endometriosis with a well-tolerated safety profile; the potential for relugolix combination therapy to evolve the treatment paradigm for women with endometriosis; and Myovant’s vision for a one pill, once-a-day, treatment option suitable for long-term use in uterine fibroids and endometriosis. Myovant Sciences' forward-looking statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, assumptions and other factors known and unknown that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by the forward-looking statements, including unforeseen circumstances or other disruptions to normal business operations arising from or related to the COVID-19 pandemic. Myovant Sciences cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could materially affect Myovant Sciences' operations and future prospects or which could cause actual results to differ materially from expectations include, but are not limited to, the risks and uncertainties listed in Myovant Sciences' filings with the United States Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in Myovant Sciences' Quarterly Report on Form 10-Q filed on November 12, 2020, as such risk factors may be amended, supplemented or superseded from time to time. These risks are not exhaustive. New risk factors emerge from time to time and it is not possible for Myovant Sciences' management to predict all risk factors, nor can Myovant Sciences assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof, and, except as required by law, Myovant Sciences undertakes no obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements. CONTACT: Mary Stutts Sumitovant Biopharma 415-419-6705 mary.stutts@sumitovant.com
Send love from afar with a gorgeous bouquet or a hearty houseplant. The post The best delivery services for sending flowers and houseplants this Valentine’s Day appeared first on In The Know.
Turner Scientific has chosen Craig A. Hodges, Ph.D., as the winner of its 2020 Sensory Sentinel grant to promote animal welfare and improved research.
NEW YORK, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Covia Holdings Corporation f/k/a Fairmount Santrol Holdings Inc. (“Covia”) (OTC: CVIAQ) (NYSE: CVIA) (NYSE: FMSA) between March 15, 2016 to June 29, 2020, inclusive (the “Class Period”). To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=covia-holdings-corporation&id=2519 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action. 如果您想加入这个集体诉讼案，请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=covia-holdings-corporation&id=2519 According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: Covia’s proprietary “value-added” proppants were not necessarily more effective than ordinary sand; Covia’s revenues, which were dependent on its proprietary “value-added” proppants, was based on misrepresentations; when Covia insiders raised this issue, defendants did not take meaningful steps to rectify the issue; and as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. If you wish to serve as lead plaintiff, you must move the Court no later than February 8, 2021. Lead plaintiff status is not required to seek compensation. You may retain counsel of your choice. You may remain an absent class member and take no action at this time. Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes. Zhang Investor Law P.C.99 Wall Street, Suite 232New York, New York 10005info@zhanginvestorlaw.comtel: (800) 991-3756
Caris LeVert will be out indefinitely as he recovers from surgery to treat renal cell carcinoma.
EDMONTON, Alberta, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Translational Research in Oncology (TRIO), a global academic clinical research organization, is pleased to be recognized as one of Alberta’s Top 70 Employers, an editorial competition that recognizes Alberta’s best places to work. “Well-being has taken on new meaning this year,” says Kristina Leung, Senior Editor of the Canada’s Top 100 Employers project. “With the uncertainty of the past year, organizations have had to go the extra distance to ensure that folks are cared for and have the necessary supports for their physical, emotional, and financial wellbeing.” “We are proud to be named one of Alberta’s Top Employers for the second year in a row,” stated Dr. Launa Aspeslet, TRIO’s Chief Executive Officer. “This past year has seen an unprecedented need for employers to get it right. Our commitment to provide a positive and engaging employee experience has never been stronger. When our employees succeed, TRIO succeeds.” About Alberta’s Top EmployersFirst published in 2006, Alberta’s Top Employers is a special designation that recognizes Alberta employers that lead their industries in offering exceptional places to work. Employers throughout Alberta were evaluated by the editors at Canada’s Top 100 Employers using the same criteria as the national competition: (1) Physical Workplace; (2) Work Atmosphere & Social; (3) Health, Financial & Family Benefits; (4) Vacation & Time Off; (5) Employee Communications; (6) Performance Management; (7) Training & Skills Development; and (8) Community Involvement. Employers are compared to other organizations in their field to determine which offer the most progressive and forward-thinking programs. The annual competition is open to any employer with its head office in Alberta, and employers of any size may apply, whether private or public sector. About TRIOTRIO advances translational cancer research by introducing innovative and novel targeted therapeutic concepts into the clinical trial setting. With international offices in Edmonton (Canada), Paris (France), Montevideo (Uruguay), TRIO’s global reach is expansive. Our goal as a not-for-profit clinical research organization is to find the shortest path to saving lives. Additional information on TRIO can be found by visiting https://www.trioncology.org. Interested parties may also follow TRIO on Twitter (twitter.com/TRIOncology) or LinkedIn at TRIO - Translational Research in Oncology. TRIO Media Inquiries:Launa Aspeslet, PhDCEO, TRIOEmail: launa.aspeslet@trioncology.orgPhone: 780-702-2260
Yahoo Finance